A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site

Biochemistry. 1991 Feb 26;30(8):2022-6. doi: 10.1021/bi00222a003.

Abstract

A novel dipyridodiazepinone, 6,11-dihydro-11-cyclopropyl-4-methyldipyrido[2,3-b:2',3'-e]- [1,4]diazepin-6-one (BI-RG-587), is a selective noncompetitive inhibitor of HIV-1 reverse transcriptase (RT-1). An azido photoaffinity analogue of BI-RG-587 was synthesized and found to irreversibly inhibit the enzyme upon UV irradiation. BI-RG-587 and close structural analogues competitively protected RT-1 from inactivation by the photoaffinity label. A thiobenzimidazolone (TIBO) derivative, a nonnucleoside inhibitor of RT-1, also protected the enzyme from photoinactivation, which suggests a common binding site for these compounds. Substrates dGTP, template-primer, and tRNA afforded no protection from enzyme inactivation. A tritiated photoaffinity probe was found to stoichiometrically and selectively label p66 such that 1 mol of probe inactivates 1 mol of RT-1.

Publication types

  • Comparative Study

MeSH terms

  • Affinity Labels / chemical synthesis
  • Affinity Labels / pharmacology
  • Antiviral Agents / pharmacology*
  • Binding Sites
  • Blood Proteins / metabolism
  • Escherichia coli / genetics
  • HIV-1 / enzymology*
  • Humans
  • Kinetics
  • Leukocytes / metabolism
  • Nevirapine
  • Protein Binding
  • Pyridines / metabolism
  • Pyridines / pharmacology*
  • RNA-Directed DNA Polymerase / metabolism
  • Recombinant Proteins / antagonists & inhibitors
  • Recombinant Proteins / metabolism
  • Reverse Transcriptase Inhibitors*
  • Structure-Activity Relationship

Substances

  • Affinity Labels
  • Antiviral Agents
  • Blood Proteins
  • Pyridines
  • Recombinant Proteins
  • Reverse Transcriptase Inhibitors
  • Nevirapine
  • RNA-Directed DNA Polymerase